^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons

Published date:
01/24/2023
Excerpt:
We report a case of a 46-year-old patient with HER2-positive breast cancer who developed resistance to pyrotinib and rapidly progressed to uncontrolled liver failure in less than a week….On the basis of the NGS results, we speculated that the rapid progression after pyrotinib resistance might be due to RET gene fusion and TP53 gene mutations. Therefore, this case report aims to alert oncologists that patients with HER2-positive breast cancer, who are resistant to pyrotinib or other targeted drugs, could experience rapid or even flare-up progression and that RET gene fusion and TP53 gene mutations might be potential causes.
DOI:
10.1097/CAD.0000000000001506